Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence
Evaluation of the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706) in combination with bevacizumab for postoperative adjuvant treatment of HCC with high-risk recurrence risk
HCC - Hepatocellular Carcinoma|Adjuvant Treatment
DRUG: Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumab
One-year recurrence-free survival rate, From enrollment to the end of treatment at 1 year
Relapse-Free Survival at 6 months, RFS6, From enrollment to the end of treatment at 6 months|Relapse-Free Survival, RFS, From enrollment to through study completion, an average of 1 year|Time To Relapse, TTR, From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 24 months
Evaluation of the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706) in combination with bevacizumab for postoperative adjuvant treatment of HCC with high-risk recurrence risk